BioCentury | Jul 13, 2009
Company News

ExperGen, Thallion cancer news

...has been started related to a dispute with ExperGen over TLN-232 (CAP-232), which Thallion (formerly Caprion Pharmaceuticals Inc....
BioCentury | Jan 21, 2008
Company News

Expergen GmbH, Thallion cancer news

...The companies settled a dispute regarding CAP-232, which Caprion Pharmaceuticals Inc. (now Thallion) licensed from Expergen in 2006...
BioCentury | Mar 19, 2007
Company News

Caprion, Ecopia deal

...Thallion Pharmaceuticals Inc. and will trade on the Toronto Stock Exchange under the symbol TLN. Caprion Pharmaceuticals Inc....
BioCentury | Feb 19, 2007
Company News

Axcan management update

...CSO Hired: Marc Riviere as VP of clinical development, formerly SVP of clinical development at Caprion Pharmaceuticals Inc. WIR...
BioCentury | Jan 8, 2007
Company News

Caprion, Ecopia deal

...advising Caprion. The companies plan to sell Caprion's CellCarta proteomics business unit within 12 months. Caprion Pharmaceuticals Inc....
BioCentury | Oct 30, 2006
Company News

Caprion, Vertex deal

...provide the same services for larger sets of VRTX samples. Further terms were not disclosed. Caprion Pharmaceuticals Inc....
BioCentury | Oct 23, 2006
Company News

Caprion, Goodwin deal

...Phase I testing. Caprion hopes to begin Phase II/III testing at the beginning of 2007. Caprion Pharmaceuticals Inc....
BioCentury | Oct 16, 2006
Company News

Caprion, J&J deal

...and is eligible for licensing fees and milestones, plus royalties. Further terms were not disclosed. Caprion Pharmaceuticals Inc....
BioCentury | May 15, 2006
Clinical News

Shigamabs regulatory update

...the U.S. and the EU. Caprion hopes to begin a Phase II/III trial by 1Q07. Caprion Pharmaceuticals Inc....
BioCentury | Apr 3, 2006
Company News

Caprion, Vertex deal

...in samples from preclinical and clinical studies conducted by VRTX. Further terms were not disclosed. Caprion Pharmaceuticals Inc....
Items per page:
1 - 10 of 48
BioCentury | Jul 13, 2009
Company News

ExperGen, Thallion cancer news

...has been started related to a dispute with ExperGen over TLN-232 (CAP-232), which Thallion (formerly Caprion Pharmaceuticals Inc....
BioCentury | Jan 21, 2008
Company News

Expergen GmbH, Thallion cancer news

...The companies settled a dispute regarding CAP-232, which Caprion Pharmaceuticals Inc. (now Thallion) licensed from Expergen in 2006...
BioCentury | Mar 19, 2007
Company News

Caprion, Ecopia deal

...Thallion Pharmaceuticals Inc. and will trade on the Toronto Stock Exchange under the symbol TLN. Caprion Pharmaceuticals Inc....
BioCentury | Feb 19, 2007
Company News

Axcan management update

...CSO Hired: Marc Riviere as VP of clinical development, formerly SVP of clinical development at Caprion Pharmaceuticals Inc. WIR...
BioCentury | Jan 8, 2007
Company News

Caprion, Ecopia deal

...advising Caprion. The companies plan to sell Caprion's CellCarta proteomics business unit within 12 months. Caprion Pharmaceuticals Inc....
BioCentury | Oct 30, 2006
Company News

Caprion, Vertex deal

...provide the same services for larger sets of VRTX samples. Further terms were not disclosed. Caprion Pharmaceuticals Inc....
BioCentury | Oct 23, 2006
Company News

Caprion, Goodwin deal

...Phase I testing. Caprion hopes to begin Phase II/III testing at the beginning of 2007. Caprion Pharmaceuticals Inc....
BioCentury | Oct 16, 2006
Company News

Caprion, J&J deal

...and is eligible for licensing fees and milestones, plus royalties. Further terms were not disclosed. Caprion Pharmaceuticals Inc....
BioCentury | May 15, 2006
Clinical News

Shigamabs regulatory update

...the U.S. and the EU. Caprion hopes to begin a Phase II/III trial by 1Q07. Caprion Pharmaceuticals Inc....
BioCentury | Apr 3, 2006
Company News

Caprion, Vertex deal

...in samples from preclinical and clinical studies conducted by VRTX. Further terms were not disclosed. Caprion Pharmaceuticals Inc....
Items per page:
1 - 10 of 48